Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

Source URL: www.anrs.fr

Agence nationale de recherches sur le sida et les hépatites virales : essais thérapeutiques VIH (aoûtANRS 167 LAMIDOL Essai pilote évaluant un traitement de maintenance par lamivudine et dolutégravir chez le

Source URL: www.anrs.fr

Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio - ViiV Healthcare acquires exclusive global rights to HIV integrase inhibitor portfolio, including dolutegrav

Source URL: shionogi616.tew-staging.com

• Intel Viiv
• Integrase inhibitors
• Organofluorides
• Pfizer
• Biology
• Pharmacology
• Dolutegravir
• Shionogi
• Pharmaceutical industry
• Pharmaceutical sciences
• ViiV Healthcare
• GlaxoSmithKline

  Once‐Daily Dolutegravir is Non‐Inferior to Twice‐Daily Raltegravir  in Treatment‐Naïve Adults with HIV‐1    

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Health
• HIV/AIDS
• Amides
• Oxadiazoles
• Raltegravir
• Lamivudine
• GlaxoSmithKline
• Dolutegravir
• Organofluorides
• Chemistry
• Integrase inhibitors

Data from the FLAMINGO Phase IIIb/IV Study of the Integrase Inhibitor Tivicay® (dolutegravir), Disclosed by ViiV Healthcare Osaka, Japan, September 13, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: I

Source URL: shionogi616.tew-staging.com

• Sulfonamides
• Medicine
• Carbamates
• Darunavir
• HIV/AIDS
• Antiretroviral drug
• ViiV Healthcare
• Zidovudine
• Integrase inhibitor
• Protease inhibitors
• Chemistry
• Biology

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Source URL: shionogi616.tew-staging.com

• Organic chemistry
• Medicine
• Amides
• Merck
• Oxadiazoles
• Raltegravir
• Integrase
• Dolutegravir
• ViiV Healthcare
• Integrase inhibitors
• Chemistry
• Organofluorides

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Source URL: shionogi616.tew-staging.com

• Integrase inhibitors
• Abacavir
• Cyclopropanes
• Purines
• Antiretroviral drug
• HIV/AIDS
• Lamivudine
• Reverse-transcriptase inhibitor
• ViiV Healthcare
• Biology
• Chemistry
• Organofluorides

Data from VIKING-3 Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, November 14, Shionogi & Co., Ltd. (Head Office: Osaka; President & C

Source URL: shionogi616.tew-staging.com

• Enzymes
• Integrase
• Microbiology
• Virology
• ViiV Healthcare
• Intel Viiv
• Shionogi
• Dolutegravir
• HIV
• Integrase inhibitors
• Biology
• Organofluorides

PDF Document

Source URL: shionogi616.tew-staging.com

• Medicine
• Intel Viiv
• Integrase
• ViiV Healthcare
• Shionogi
• New Drug Application
• HIV
• Food and Drug Administration
• Dolutegravir
• Integrase inhibitors
• Pharmaceutical sciences
• Biology

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

Source URL: shionogi616.tew-staging.com

• Organofluorides
• Medicine
• Fixed dose combination
• Bristol-Myers Squibb
• Cyclopropanes
• Emtricitabine/tenofovir/efavirenz
• Antiretroviral drug
• Abacavir
• Lamivudine
• Chemistry
• Pharmacology
• Gilead Sciences